EPI-506
EPI-506 (developed by Essa Pharma) is an experimental compound in phase I/II development for prostate cancer.[1] It is the successor of EPI-001 and targets the N-terminal domain of the androgen receptor. This mechanism of action is believed to allow the drug to block signaling from the androgen receptor and its splice variants.[2][3]
References
- ↑ "Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-02-27.
- ↑ "A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.". Journal of Clinical Oncology. ISSN 0732-183X.
- ↑ Silberstein, John L.; Taylor, Maritza N.; Antonarakis, Emmanuel S. (2016-02-23). "Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer". Current Urology Reports 17 (4): 1–10. doi:10.1007/s11934-016-0584-4. ISSN 1527-2737.
|
This article is issued from Wikipedia - version of the Tuesday, May 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.